ClinicalTrials.gov
ClinicalTrials.gov Menu

Studying the Effects of Phentermine on Eating Behavior

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01886937
Recruitment Status : Completed
First Posted : June 26, 2013
Results First Posted : July 31, 2017
Last Update Posted : July 31, 2017
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
New York State Psychiatric Institute

Brief Summary:
The goal of this study is to determine whether one week of phentermine compared to placebo administration results in changes in food intake during a laboratory meal.

Condition or disease Intervention/treatment Phase
Obesity Drug: Phentermine Drug: placebo Phase 4

Detailed Description:
This study aims to explore whether short-term measures of eating behavior can be related to later, longer-term weight loss. In a double-blind, randomized fashion, participants will be asked to take study medication for three weeks: one week of phentermine and two weeks of placebo. At the end of the first and third weeks, participants will be asked to participate in a range of eating behavior studies. Following this three-week, double-blind phase, participants will be offered 6 months of open treatment for weight loss.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Other
Official Title: The Quantification of Ingestive Behavior
Study Start Date : July 2012
Actual Primary Completion Date : June 2014
Actual Study Completion Date : June 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 37.5 mg Phentermine daily for 7 days

In this arm, participants receive 37.5mg phentermine for one week followed by 2 weeks of placebo.

Other names for phentermine:

adipex ionamin

Drug: Phentermine
After 7 days of phentermine 37.5 mg administration, food intake should be less than after 14 days of placebo.
Other Names:
  • adipex
  • ionamin

Placebo Comparator: Placebo (for phentermine 37.5mg)
In this arm, participants receive Placebo (for 37.5mg phentermine) for two weeks followed by phentermine 37.5mg for 7 days.
Drug: placebo
Food intake as measured by a laboratory study should be greater after 7 days of placebo administration compared to seven days of phentermine administration.
Other Name: sugar pill




Primary Outcome Measures :
  1. Food Intake [ Time Frame: one week ]
    The primary outcome measure is food intake assessed by laboratory meal study after one week of phentermine administration compared to one week of placebo administration.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • BMI between 30-40kg/m2
  • Stable weight (+5 lbs) for a minimum of 3 months
  • Systolic Blood Pressure <140mm Hg
  • Diastolic Blood Pressure <90 mm Hg
  • Pulse <95 beats per minute
  • English language proficiency

Exclusion Criteria:

  • Previous unsuccessful trial of phentermine
  • Prior adverse reaction to phentermine
  • On any antidepressant medications,especially monoamine oxidase inhibitors(MAOI)
  • History of neurological disorder (e.g. dementia)
  • History of moderate or severe head injury
  • Current or past history of coronary artery disease
  • Current or past history of stroke or transient ischemic attack
  • Current or past history of heart arrhythmias
  • Current of past history of congestive heart failure
  • Current or past history of peripheral artery disease
  • Current or past history of liver disease
  • Current or past history of kidney disease
  • Uncontrolled diabetes mellitus (type I or II)
  • Narrow-angle glaucoma
  • Hypo- or hyper-thyroidism not adequately treated
  • On medications (prescribed or OTC) known to affect appetite (e.g. diet pills), weight, or metabolism
  • Current or past history (within the past 12 months) of major depression
  • Current or past history (past 12 months) of alcohol or drug abuse or dependence
  • Current or past history (lifetime) of amphetamine abuse or dependence
  • Known history of learning disorder or developmental disability
  • Current or past Attention Deficit Hyperactivity Disorder (ADHD)
  • Pregnancy, planning to become pregnant, or lactation within the previous 6 months
  • Waist circumference greater than 188cm
  • Indwelling metallic object (e.g., pacemaker,pump), non-removable metal jewelry, medicinal patch or recent metallic ink tattoo
  • Significant claustrophobia
  • Current or past history of anorexia nervosa,bulimia nervosa (within the past 12 months) or binge eating disorder (within the previous 6 months)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01886937


Locations
United States, New York
The New York State Psychiatric Institute at Columbia University Medical Center
New York, New York, United States, 10032
Sponsors and Collaborators
New York State Psychiatric Institute
AstraZeneca
Investigators
Principal Investigator: Laurel Mayer, MD Columbia University Medical Center/New York State Psychiatric Institute

Responsible Party: New York State Psychiatric Institute
ClinicalTrials.gov Identifier: NCT01886937     History of Changes
Other Study ID Numbers: 6415
First Posted: June 26, 2013    Key Record Dates
Results First Posted: July 31, 2017
Last Update Posted: July 31, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Phentermine
Central Nervous System Stimulants
Physiological Effects of Drugs
Appetite Depressants
Anti-Obesity Agents
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action